Seeking Alpha
16 Aug 2026, 12:00 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Assembly Biosciences has multiple phase 2 trials for GS-1179 and ABI-6250 with readouts expected between 2027 and 2028. — Clinical trial readouts are primary value drivers for biotech firms, though the long time horizon moderates immediate impact.
+0.50The partnership with Gilead on GS-1179 allows for either milestone/royalty payments or a 40% cost-profit share. — Strategic optionality and profit-sharing with a major pharma partner increase the potential financial upside upon commercialization.
+0.40Assembly Biosciences maintains a strong cash position. — Adequate liquidity reduces the immediate risk of dilutive capital raises, which is critical for pre-revenue biotech companies.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
11h ago
